A Phase 1 interventional study of NI-0701 and Placebo in Healthy Volunteers, sponsored by Light Chain Bioscience - Novimmune SA. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-07.
Sponsored by Light Chain Bioscience - Novimmune SA · Phase 1 and Interventional
The purpose of this study is to determine the safety, pharmacodynamic and pharmacokinetic profiles of a novel therapeutic drug when administered to healthy volunteers.
Light Chain Bioscience - Novimmune SA is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: NI-0701
Drug: Placebo
Safety and tolerability of escalating single IV doses of NI-0701 in healthy volunteers
NI-0701 Pharmacokinetic parameters in healthy volunteers
NI-0701 plasma pharmacodynamic effects upon NI-0701 single intravenous infusion
Pharmacodynamic effects of NI-0701 on Histamine skin-induced wheal and flare
Immunogenicity of NI-0701
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Light Chain Bioscience - Novimmune SA